Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Conventional systemic agents for psoriasis. A systematic review.

Bruce E Strober1, Kimberly Siu, Kavi Menon

  • 1New York University School of Medicine, New York, New York 10016, USA. Strober@nyc.rr.com

The Journal of Rheumatology
|May 26, 2006
PubMed
Summary

This review examines systemic psoriasis treatments like cyclosporine and methotrexate, assessing their effectiveness and safety. Evidence-based recommendations are provided for these conventional therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial.

JAMA dermatology·2026
Same author

Envudeucitinib, a Potent, Next-Generation, Allosteric Inhibitor of TYK2: A Narrative Review.

Dermatology and therapy·2026
Same author

Brodalumab's 8-Year Journey in Plaque Psoriasis: Insights into Efficacy, Safety, and Real-World Evidence.

Journal of drugs in dermatology : JDD·2026
Same author

Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitors.

Journal of the American Academy of Dermatology·2025
Same author

Establishing consensus on defining failure of topical therapy in psoriasis: Recommendations from the International Psoriasis Council.

Journal of the American Academy of Dermatology·2025
Same author

Systemic Corticosteroid Use in Atopic Dermatitis: A Position Paper to Inform Safer Clinical Practice and Policy.

The Journal of investigative dermatology·2025

Area of Science:

  • Dermatology
  • Pharmacology
  • Evidence-Based Medicine

Background:

  • Psoriasis is a chronic inflammatory skin condition with limited well-designed studies on conventional systemic agents.
  • Systemic therapies are crucial for moderate-to-severe psoriasis but require careful evaluation.

Purpose of the Study:

  • To systematically review the literature on the efficacy and safety of conventional systemic agents for psoriasis.
  • To provide evidence-based treatment recommendations for commonly used systemic psoriasis medications.

Main Methods:

  • Systematic literature review of well-designed studies.
  • Evaluation of efficacy and safety data for specific agents.
  • Synthesis of evidence to formulate treatment guidelines.

Related Experiment Videos

Main Results:

  • Cyclosporine, methotrexate, and acitretin show significant efficacy but have distinct safety profiles.
  • Hydroxyurea and 6-thioguanine have limited evidence for psoriasis treatment efficacy and safety.
  • Risk-benefit assessments vary among agents, influencing treatment selection.

Conclusions:

  • Conventional systemic agents like cyclosporine and methotrexate remain important for psoriasis management.
  • Acitretin offers an alternative with specific considerations for efficacy and side effects.
  • Further high-quality research is needed to optimize the use of these agents and explore newer therapies.